Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Alliance, apoptotic, Australia, Biology, CBCA, compelling, conference, convenience, country, diagnosed, Director, discourage, ESH, Estoril, failure, featured, Fed, frontline, fully, growing, Haematology, Houston, Institutional, irrevocable, Korean, lethal, naive, newly, Notably, ORR, parental, party, payable, perpetual, phosphokinome, population, Portugal, pro, proteome, rapidly, reorganization, salvage, software, Spain, staggered, subscription, tablet, tiered, tranche, Translational, unusually, upfront, vulnerability
Removed:
base, comprising, declared, distribute, filing, shelf, short, voting
Filing tables
Filing exhibits
Related press release
Associated APTO transcripts
APTO similar filings
Filing view
External links
Exhibit 32.1
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, William G. Rice, the President and Chief Executive Officer of Aptose Biosciences Inc. (the “Company”), hereby certify that, to my knowledge:
1.
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2023
/s/ William G. Rice Name: William G. Rice, Ph.D. Title: President and Chief Executive Officer |